1
Participants
Start Date
October 31, 2008
Primary Completion Date
November 30, 2008
Study Completion Date
November 30, 2008
ezatiostat hydrochloride (Telintra®)
4500 mg orally per day in two divided doses
Montefiore Medical Center, The Bronx
Suburban Hematology-Oncology Associates, PC, Lawrenceville
Florida Hospital Cancer Institute, Ormand Beach
Broward Oncology Associates, Fort Lauderdale
Lakeland Regional Cancer Center, Lakeland
Nature Coast Clinical Research, Inverness
Case Medical Center-University Hospitals, Cleveland
Joliet Oncology/Hematology Associates, Ltd., Joliet
Medical & Surgical Specialists, Galesburg
The University of Oklahoma Health Sciences Center, Oklahoma City
Comprehensive Cancer Centers of Nevada, Henderson
UCLA Medical Center, Los Angeles
Clinical Trials and Research Associates, Inc., Montebello
North Valley Hematology/Oncology Medical Group, Northridge
Providence St. Joseph Medical Center, Burbank
Wilshire Oncology Medical Group, La Verne
Central Hematology Oncology Medical Group, Alhambra
Pacific Cancer Medical Center, Inc., Anaheim
St. Jude Heritage Healthcare, Fullerton
Ventura County Hematology-Oncology Specialists, Oxnard
Samsum Clinic, Santa Barbara
Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara
Central Coast Medical Oncology Corporation, Santa Maria
Coastal Cancer Center, Myrtle Beach
Lead Sponsor
Telik
INDUSTRY